Bio-Rad Laboratories, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by Bio-Rad Laboratories, Inc. on April 28, 2020. The filing details the outcomes of three specific proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following matters were voted upon and approved by the majority of votes cast:
- Election of Directors: All nominated directors were elected.
- Class A Directors: Melinda Litherland and Arnold A. Pinkston received significant affirmative votes (approx. 17.9M and 18.1M respectively) with minimal votes against.
- Class B Directors: Jeffrey L. Edwards, Gregory K. Hinckley, Alice N. Schwartz, and Norman Schwartz were elected with overwhelming support, receiving only 413 to 2,591 votes against.
- Ratification of Auditors: The selection of KPMG LLP as independent auditors for the fiscal year ending December 31, 2020, was ratified with 6,757,921 votes for and only 803 votes against.
- Executive Compensation: The non-binding advisory vote to approve executive compensation was approved with 6,565,329 votes for and 190,109 votes against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirm the full slate of directors elected for the upcoming term.
- Verify the appointment of KPMG LLP as the independent auditor for fiscal year 2020.
- Note the level of shareholder support for executive compensation (approx. 97% affirmative).
- Review the specific vote counts for Class A versus Class B stock to understand voting power distribution.